Completeness of the dataset (%) - stage complete by cancer site groups summary (persons)
| Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | Republic of Ireland | |
|---|---|---|---|---|---|---|---|
| All invasive xnmsc | 80.6% | 77.9% | 81.9% | 67.2% | 84.7% | ||
| Haematology | 67.0% | 50.6% | 71.9% | 0.0% | 79.9% | ||
| Head and Neck | 88.6% | 86.6% | 89.9% | 76.8% | 93.2% | ||
| Lower GI | 88.8% | 84.8% | 90.4% | 73.6% | 90.5% | ||
| Upper GI | 80.6% | 72.6% | 82.5% | 67.8% | 67.5% | ||
| HPB | 71.0% | 72.6% | 70.7% | 72.9% | 74.3% | ||
| Trachea, Bronchus & Lung | 93.2% | 93.2% | 93.4% | 91.7% | 94.6% | ||
| Melanoma of skin | 89.8% | 77.2% | 94.6% | 38.8% | 98.2% | ||
| Breast | 92.7% | 91.4% | 93.4% | 84.8% | 96.1% | ||
| Cervix | 92.7% | 95.6% | 92.1% | 95.9% | 98.8% | ||
| Other Female Genitals | 86.7% | 86.1% | 87.5% | 76.0% | 94.8% | ||
| Prostate | 90.0% | 89.4% | 90.3% | 84.3% | 93.6% | ||
| Bladder | 84.9% | 79.3% | 87.4% | 59.2% | 91.4% | ||
| Kidney | 86.2% | 85.4% | 87.1% | 74.1% | 95.0% | ||
| Thyroid and other endocrine glands | 72.1% | 82.6% | 70.7% | 78.9% | 98.1% | ||
| Other invasive cancer | 62.5% | 51.6% | 66.3% | 25.4% | 63.1% | ||
| Non-Melanoma Skin Cancer | 4.2% | 5.3% | 4.3% | 0.0% | 11.7% |